
West Pharmaceutical Services statistics
$416.42+1.24%Close 13 Nov 2026
Valuation and share-price figures are struck on the latest close (13 Nov 2026); the others are read from the company's reports. A figure that cannot be worked out, such as a P/E after a loss, is left out.
Valuation
| Enterprise value | $28.91B |
|---|
| EV / EBITDA | 29.97 |
|---|
| EV / sales | 8.51 |
|---|
Share price
| Latest close | $416.42 |
|---|
| Day's change | +1.2% |
|---|
| 52-week high | $438.27 |
|---|
| 52-week low | $223.83 |
|---|
| From 52-week high | −5.0% |
|---|
| Return · 1 month | +8.4% |
|---|
| Return · 3 months | +17.7% |
|---|
| Return · year to date | +51.3% |
|---|
| Return · 1 year | +52.1% |
|---|
| Beta · 1 year against the S&P 500 | 0.65 |
|---|
| 50-day average | $380.18 |
|---|
| 200-day average | $321.39 |
|---|
| RSI 14 | 65.8 |
|---|
| Average volume · 20 sessions | 764K |
|---|
Margins and returns
For fiscal 2025, as filed.
| Gross margin | 35.9% |
|---|
| Operating margin | 19.0% |
|---|
| Net margin | 16.1% |
|---|
| Free cash flow margin | 15.3% |
|---|
| Return on equity | 16.9% |
|---|
| Return on assets | 11.8% |
|---|
| Return on invested capital | 16.7% |
|---|
| Return on capital employed | 17.4% |
|---|
| Stock-based compensation / revenue | 0.8% |
|---|
Financial position
At the end of fiscal 2025.
| Cash and equivalents | $791.3M |
|---|
| Total debt | $321.1M |
|---|
| Net debt | −$470.2M |
|---|
| Current ratio | 3.02 |
|---|
| Debt / equity | 0.10 |
|---|
| Net debt / EBITDA | −0.62 |
|---|
| Interest coverage | 1169.80 |
|---|
Shares and dividends
For fiscal 2025, as filed.
| Diluted shares | 72.7M |
|---|
| Net share repurchases | $122.7M |
|---|
| Dividends per share | $0.86 |
|---|
| Dividend payout | 12.4% |
|---|
Taxes
For fiscal 2025, as filed.
| Income tax expense | $121.6M |
|---|
| Effective tax rate | 20.2% |
|---|
WST in the terminal
Valuation against the company's own history, a cash-flow valuation, peers, charts and alerts.